Biocept begins subject enrolment in CNSide assay trial
The trial will assess CNSide’s performance in tracking the response of leptomeningeal metastases to treatment.

The trial will assess CNSide’s performance in tracking the response of leptomeningeal metastases to treatment.
The platform provides optional predictive analytics as well as extra security to protect user accounts.
Medtronic’s GAAP net income for the reported quarter was $1.222bn, representing a 17% decline.
Covid-19 tests market remains resilient
Qritive launches new AI-powered tool for prostate cancer diagnosis
AI-powered software launched by Genomic Vision
Lack of trust in AI-led electronic health systems remains